Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Market price (% of par)
-
185.94%
-
Total 13F principal
-
$400,835,000
-
Principal change
-
+$304,266,000
-
Total reported market value
-
$745,876,060
-
Number of holders
-
37
-
Value change
-
+$577,341,623
-
Number of buys
-
33
-
Number of sells
-
5
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q2 2021
As of 30 Jun 2021,
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 was held by
37 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$400,835,000
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, WOLVERINE ASSET MANAGEMENT LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., MACKAY SHIELDS LLC, BAKER BROS. ADVISORS LP, WELLS FARGO & COMPANY/MN, LAZARD ASSET MANAGEMENT LLC, and LMR Partners LLP.
This page lists
38
institutional bondholders reporting positions
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.